None of the 29 investors followed here reported a position in AMLX in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a AMLX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 4, 2026 | Milne George Mclean JrDirector | Sale at price 27.70 per share. | 30K | $830.90K |
| Sep 9, 2026 | Bedrosian Camille LOfficer | Sale at price 32.21 - 33.09 per share. | 10K | $324.87K |
| Sep 9, 2026 | Frates James MatthewChief Financial Officer | Sale at price 32.27 - 33.23 per share. | 10.8K | $349.82K |
| Sep 9, 2026 | Cohen Joshua BarryChief Executive Officer | Sale at price 32.16 - 33.15 per share. | 30.5K | $980.50K |
| Sep 9, 2026 | Klee Justin BChief Executive Officer | Sale at price 32.13 - 33.16 per share. | 30.5K | $980.26K |
| Sep 9, 2026 | Mazzariello GinaOfficer | Sale at price 32.46 - 33.34 per share. | 9.5K | $309.51K |
| Aug 30, 2026 | Firestone Karen M.Director | Conversion of Exercise of derivative security at price 1.76 - 5.05 per share. | 50K | $170.25K |
| Aug 17, 2026 | Bedrosian Camille LOfficer | Stock Award(Grant) at price 0.00 per share. | 22.8K | — |
| Aug 17, 2026 | Frates James MatthewChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 22.8K | — |
| Aug 17, 2026 | Cohen Joshua BarryChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 60K | — |
| Aug 17, 2026 | Klee Justin BChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 60K | — |
| Aug 17, 2026 | Mazzariello GinaOfficer | Stock Award(Grant) at price 0.00 per share. | 21.3K | — |
| Jul 9, 2026 | Mazzariello GinaOfficer | Sale at price 17.61 - 18.32 per share. | 30K | $538.87K |
| May 20, 2026 | Firestone Karen M.Director | Purchase at price 13.51 per share. | 3.8K | $51.34K |
| Mar 4, 2026 | Bedrosian Camille LOfficer | Stock Award(Grant) at price 0.00 per share. | 96K | — |
| Mar 4, 2026 | Frates James MatthewChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 96K | — |
| Mar 4, 2026 | Cohen Joshua BarryChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 248.9K | — |
| Mar 4, 2026 | Klee Justin BChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 248.9K | — |
| Mar 4, 2026 | Mazzariello GinaOfficer | Stock Award(Grant) at price 0.00 per share. | 74.7K | — |
| Mar 1, 2026 | Bedrosian Camille LOfficer | Sale at price 14.58 per share. | 6.5K | $94.20K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 18.3 | 6.2 | -8.4 | 15.1 | -10.3 | 25.2 | 13.1 | 66.2 | -13.8 | -6.7 | +124.8% | ||
| 2025 | -3.4 | -10.1 | 7.9 | 44.4 | 0.8 | 24.5 | 25.3 | 16.8 | 44.9 | 2.5 | 7.5 | -19.4 | +219.6% |
| 2024 | 8.7 | 17.8 | -84.9 | -36.3 | -5.0 | 10.5 | 8.4 | 7.8 | 45.9 | 66.7 | 2.6 | -31.8 | −74.3% |
| 2023 | 6.1 | -11.2 | -15.7 | -3.2 | -13.1 | -12.6 | 8.7 | -8.1 | -15.1 | -10.9 | -13.2 | 4.0 | −60.2% |
| 2022 | 41.9 | -60.9 | -30.0 | -1.2 | 116.6 | 40.1 | -6.5 | 11.5 | 26.7 | 7.6 | -3.7 | +59.4% |
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Buy / hold / sell counts